Top

Published in:

Open Access 01-12-2017 | Review

Current role of perampanel in pediatric epilepsy

Authors: Paola De Liso, Romina Moavero, Giangennaro Coppola, Paolo Curatolo, Raffaella Cusmai, Giovambattista De Sarro, Emilio Franzoni, Federico Vigevano, Alberto Verrotti

Published in: Italian Journal of Pediatrics | Issue 1/2017

Abstract

Perampanel is among the latest AEDs approved, indicated for the treatment of partial-onset seizures with or without secondary generalization, and for primary generalized tonic-clonic seizures, in patients aged 12 years and older. This paper summarizes the clinical recommendations on the current role of perampanel in the treatment of pediatric epilepsies and future directions for research. The optimal dosage should be comprised between 4 and 12 mg/day, with 8 mg/day being the most common dosage used. The rate and severity of adverse events, including psychiatric symptoms, can be decreased by starting at low doses, and titrating slowly. Overall, perampanel presents an acceptable risk/benefit ratio, but special caution should be made to the risk of seizure aggravation and behavioral problems. The favorable cognitive profile, the ease of use of the titration scheme and the once-daily formulation offer advantage over other AEDs and make this drug particularly suitable for adolescent population. Perampanel is a welcome addition to the armamentarium of the existing AEDs, as it represents a new approach in the management of epilepsy, with a novel mechanism of action and a potential to have a considerable impact on the treatment of adolescents with epilepsy.

Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord: Int Epilepsy J Videotape. 2015;17(2):117–23.

Zuberi SM, Symonds JD. Update on diagnosis and management of childhood epilepsies. J Pediatr. 2015;91(6 Suppl 1):S67–77.CrossRef

Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331–40.CrossRefPubMed

Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19–24.CrossRef

Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta neurologica Scandinavica Supplementum. 2013(197):9-18.

Citraro R, Aiello R, Franco V, De Sarro G, Russo E. Targeting alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. Expert Opin Ther Targets. 2014;18(3):319–34.CrossRefPubMed

Hanada T, Ido K, Kosasa T. Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol res Perspect. 2014;2(5):e00063.CrossRefPubMedPubMedCentral

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the tenth Eilat conference (EILAT X). Epilepsy res. 2010;92(2-3):89–124.CrossRefPubMed

Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.CrossRefPubMed

10.

Franco V, Iudice A, Grillo E, Citraro R, De Sarro G, Russo E. Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. Expert Opin Pharmacother. 2014;15(5):637–44.CrossRefPubMed

11.

Franco V, Marchiselli R, Fattore C, Tartara E, De Sarro G, Russo E, et al. Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug Perampanel in human plasma. Ther Drug Monit. 2016;38(6):744–50.CrossRefPubMed

12.

Villanueva V, Majid O, Nabangchang C, Yang H, Laurenza A, Ferry J, et al. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. Epilepsy res. 2016;127:126–34.CrossRefPubMed

13.

French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589–96.CrossRefPubMedPubMedCentral

14.

Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–15.CrossRefPubMed

15.

French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117–25.CrossRefPubMed

16.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013;54(1):126–34.CrossRefPubMed

17.

Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19(4):435–45.CrossRefPubMed

18.

Lagae L, Villanueva V, Meador KJ, Bagul M, Laurenza A, Kumar D, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016;57(7):1120–9.CrossRefPubMed

19.

Biro A, Stephani U, Tarallo T, Bast T, Schlachter K, Fleger M, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015;46(2):110–6.CrossRefPubMed

20.

De Liso P, Vigevano F, Specchio N, De Palma L, Bonanni P, Osanni E, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy res. 2016;127:93–100.CrossRefPubMed

21.

French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy a randomized trial. Neurology. 2015;85(11):950–7.CrossRefPubMedPubMedCentral

22.

Schorlemmer K, Bauer S, Belke M, Hermsen A, Klein KM, Reif PS, et al. Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease). Epilepsy Behav Case Rep. 2013;1:118–21.CrossRefPubMedPubMedCentral

23.

Dirani M, Nasreddine W, Abdulla F, Beydoun A. Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Rep. 2014;2:164–6.CrossRefPubMedPubMedCentral

24.

Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016;62:132–5.CrossRefPubMed

25.

Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481–9.CrossRefPubMed

26.

Heyman E, Lahat E, Levin N, Epstein O, Lazinger M, Berkovitch M, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol. 2016;59:441–44.

27.

Juhl S, Rubboli G. Perampanel as add-on treatment in refractory focal epilepsy. Dianalund Experience Acta Neurol Scand. 2016;134(5):374–7.CrossRefPubMed

28.

Huber B, Schmid G. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment. Epilepsy Behav. 2017;66:74–9.CrossRefPubMed

29.

Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, Schelhaas HJ, Majoie MH. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav. 2017;66:64–7.CrossRefPubMed

30.

Garamendi-Ruiz I, Garcia-Garcia ME, Bertol-Alegre V, Mauri-Llerda JA, Garcia-Morales I, Garayoa-Irigoyen V, et al. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability. Epileptic Disord. 2016;18(2):173–80.PubMed

31.

Meador KJ, Yang H, Pina-Garza JE, Laurenza A, Kumar D, Wesnes KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57(2):243–51.CrossRefPubMedPubMedCentral

32.

Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252–63.CrossRefPubMedPubMedCentral

33.

Villanueva V, Garces M, Lopez-Gonzalez FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy res. 2016;126:201–10.CrossRefPubMed

Title: Current role of perampanel in pediatric epilepsy
Authors: Paola De Liso
Romina Moavero
Giangennaro Coppola
Paolo Curatolo
Raffaella Cusmai
Giovambattista De Sarro
Emilio Franzoni
Federico Vigevano
Alberto Verrotti
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Italian Journal of Pediatrics / Issue 1/2017
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-017-0368-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current role of perampanel in pediatric epilepsy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Novel insight into Chronic Inflammatory Demyelinating Polineuropathy in APECED syndrome: molecular mechanisms and clinical implications in children

Newborn hearing screening protocol in tuscany region

Efficacy and safety of early supplementation with 800 IU of vitamin D in very preterm infants followed by underlying levels of vitamin D at birth

Clinical and epidemiological profiles including meteorological factors of low respiratory tract infection due to human rhinovirus in hospitalized children

Sedation and analgesia practices at Italian neonatal intensive care units: results from the EUROPAIN study